Clinical trials
Primary Breast Cancer clinical trials
Below are recruiting primary breast cancer clinical trials, each written for real people, not researchers. We’re tracking 719 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT04079049RecruitingPhase 3
Local treatment for breast cancer spread to the liver
This study tests a local (targeted) approach for breast cancer that has spread to the liver. It looks at whether treating liver metastases with planned liver surgery, along with standard cancer treatment before and after, can improve outcomes.
UmeåAges 18 years+ - NCT05327543Recruiting
Online yoga program for better quality of life
This study tests whether doing online yoga can improve quality of life in people with non-metastatic breast cancer. It’s meant to help with day-to-day well-being after cancer treatment.
Berlin, State of BerlinAges 18–75 - NCT05906407Recruiting
Genetic-guided treatment planning for high-risk early breast cancer
This study uses tumor genetic testing to help plan more precise treatment for people with early high-risk breast cancer. You may be asked to give a recent tumor sample so researchers can match your cancer features with the best available options.
AugsburgAges 18–80 - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT06697158Recruiting
Lymphedema therapy and its effect on sleep and quality of life
This study tests a treatment called complex decongestive physiotherapy for women who have swelling in one arm after breast cancer surgery. It looks at whether this therapy can improve their sleep and overall quality of life.
BoluAges 18–85 - NCT06738966RecruitingPhase 1
BL0175 for advanced HR-positive breast or gynecologic cancer
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
Changchun, JilinAges 18 years+ - NCT06762483Recruiting
Blood test for gene changes in advanced breast cancer
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Milan, ItalyAges 18 years+ - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06962163Recruiting
PET scan study for metastatic triple negative breast cancer
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
Saint-HerblainAges 18 years+ - NCT07135661Recruiting
Comparing two proton radiation schedules for early breast cancer after lumpectomy
This study compares two types of proton radiation after lumpectomy for early breast cancer. It tests whether a shorter, stronger course (ultra-hypofractionated) works as well as a slightly longer moderate course.
ShanghaiAges 40 years+ - NCT07190443RecruitingPhase 3
Abemaciclib after local recurrence in HR+ HER2- breast cancer
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Koto-ku, TokyoAges 18 years+ - NCT07314073RecruitingPhase 2
A PET scan to find hidden spread in slow-growing breast cancer
This trial is testing a special PET scan (18F-FES PET/CT) to see if it can find distant cancer spread in women with a slow-growing, estrogen receptor-positive, stage III breast cancer. The goal is to find out whether this imaging test can detect hidden metastases better than standard scans.
SeoulAges 19 years+ - NCT07418125Recruiting
Study of tumor cell clusters in high-risk early breast cancer
This trial looks at whether clusters of tumor cells in the blood can give more information about high-risk early breast cancer. It is for people with certain types of breast cancer who are about to start treatment before surgery (neoadjuvant therapy).
LjubljanaAges 18 years+ - NCT05019690RecruitingPhase 1/Phase 2
Test drug combo for advanced triple-negative breast cancer
This trial studies how well apatinib plus albumin-bound paclitaxel works for advanced triple-negative breast cancer that has come back or spread. It may help shrink tumors and control the disease by targeting cancer growth in more than one way.
Fuzhou, FujianAges 18–75 - NCT06470347RecruitingPhase 1/Phase 2
Testing Pyrrolitinib After Trastuzumab for HER2+ Breast Cancer
This study tests if taking pyrrolitinib (a targeted medicine) can further reduce the risk of breast cancer returning in patients with HER2-positive early breast cancer who have already received trastuzumab after surgery.
Zunyi, GuizhouAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT05130801RecruitingPhase 1/Phase 2
MRI and pHLIP dye during breast surgery to map tumors
This trial tests whether a special MRI and an injected light-activated dye (pHLIP® ICG) can help doctors see and target breast cancer during surgery. You may be offered this approach around the time of breast-conserving surgery, to improve how well the tumor area is identified.
Montvale, New JerseyAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06162559RecruitingPhase 1
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
AmsterdamAges 18 years+ - NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT07016399RecruitingPhase 2
Darolutamide before surgery for AR-positive triple-negative breast cancer
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Nashville, TennesseeAges 18 years+ - NCT07252986Recruiting
AI study of breast cancer that has spread
This study uses artificial intelligence to analyze tissue samples from breast cancer that has spread to distant organs, like the liver or lungs. The goal is to develop a tool that predicts how breast cancer might spread, helping doctors personalize treatment.
Hangzhou, ZhejiangAges Any age
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary breast cancer?
- Yes. Clin2 currently lists 719 recruiting primary breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.